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Abstract
Introduction. Intermediate syndrome (IMS) was described a
few decades ago, however, there is still a controversy regard-
ing its exact etiology, risk factors, diagnostic parameters and
required therapy. Considering that acute poisonings are
treated in different types of medical institutions this serious
complication of organophosphate insecticide (OPI) poison-
ing is frequently overlooked. The aim of this paper was to
present a case of IMS in organophosphate poisoning, which,
we believe, provides additional data on the use of oxime or
atropine. Case report. After a well-resolved cholinergic crisis,
the patient developed clinical presentation of IMS within the
first 72 h from deliberate malathion ingestion.  The signs of
IMS were weakness of proximal limb muscles and muscles
innervated by motor cranial nerves, followed by the weakness
of respiratory muscles and serious respiratory insufficiency.
Malathion and its active metabolite were confirmed by ana-
lytical procedure (liquid chromatography-mass spectrometry).
Pralidoxime methylsulphate, adiministered as a continuous in-
fusion until day 8 (total dose 38.4 g), and atropine until the
day 10 (total dose 922 mg) did not prevent the development
of IMS, hence the mechanical ventilation that was stopped
after 27 h had to be continued until the day 10. Conclusion.
Continuous pralidoxime methylsulphate infusion with atro-
pine did not prevent the development of IMS, most likely due
to the delayed treatment and insufficient oxime dose but also
because of chemical structure and lipophilicity of ingested
OPI. A prolonged intensive care monitoring and respiratory
care are the key management for the intermediate syndrome.
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Apstrakt
Uvod. Intermedijerni sindrom (IMS) opisan je pre nekoliko
decenija, meĀutim i dalje postoje kontroverze u vezi sa nje-
govom etiologijom, faktorima rizika, dijagnostiÿkim para-
metrima i potrebnom terapijom. S obzirom na to da se
akutna trovanja leÿe u medicinskim ustanovama razliÿitog
tipa, ova teška komplikacija akutnih trovanja organofosfor-
nim insekticidima (OFI) ÿesto se ne prepoznaje. Cilj rada
bio je da se prikaže sluÿaj akutnog trovanja organofosfornim
insekticidom koji ýe dati dodatne podatke o upotrebi oksi-
ma i atropina. Prikaz bolesnika. Nakon kupirane holiner-
giÿke krize kod bolesnika, 72 h od namerne ingestije malati-
ona, došlo je do razvoja kliniÿke slike IMS. Znaci IMS su
ukljuÿivali slabost mišiýa gornjih ekstremiteta i mišiýa iner-
visanih motornim kranijalnim nervima, što je bilo praýeno
slabošýu respiratorne muskulature i teškom respiratornom
insuficijencijom. Malation i njegov aktivni metabolit potvr-
Āeni su analitiÿkom procedurom (teÿna hromatografija-
masena spektrometrija). Kontinuiranom infuzijom pralidok-
sim metilsulfata do osmog dana (ukupno 38,4 g) i atropina
do desetog dana (ukupna doza 922 mg), nije spreÿen razvoj
IMS, te je mehaniÿka ventilacija, koja je prekinuta nakon 27
h, morala biti nastavljena do desetog dana. Zakljuÿak.
Kontinuiranom infuzijom pralidoksim-metilsulfata i atropi-
na nije spreÿen razvoj IMS, najverovatnije zbog odloženog
poÿetka leÿenja i nedovoljne doze primenjenog oksima, ali i
hemijske strukture i lipofilnosti ingestiranog OFI. Istaknut
je znaÿaj produžene opservacije u jedinici intenzivne nege i
respiratorne podrške u leÿenju intermedijernog sindroma.
Kljuÿne reÿi:
trovanje; estri fosforne kiseline; neurotoksiÿnost,
sindromi; atropin; oksimi; disanje, veštaÿko; leÿenje,
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Introduction
The intermediate syndrome (IMS) is a delayed onset of
muscular weakness and paralysis that occurs 1–4 days after
the resolution of acute cholinergic syndrome in acute orga-
nophosphate (OP) poisoning
 1. It was first reported by Wadia
et al. 
2 in 1974 as the “type II paralysis after organophos-
phate poisoning“. In 1987 Senanayake and Karalliede in
1987 termed this pattern of weakness as “intermediate syn-
drome” as the symptoms and signs occurre before OP induce
delayed polyneuropathy. Clinically, IMS is characterized by
acute paralysis and weakness in the territories of several cra-
nial motor nerves, neck flexors, facial, extraocular, palatal,
nuchal, proximal limb, and respiratory muscles. Although
this syndrome has been described for decades, due to some-
times diverse clinical picture, it often remains undiagnosed,
at least until the occurrence of significant respiratory weak-
ness. The controversy exists regarding not only the question
of whether IMS is a clearly defined entity, but also its exact
etiology, risk factors, diagnostic parameters and required
therapy 
1–3.
Case report
A farmer, at the age of 54, was brought to the Emer-
gency Department of a regional medical center in a coma,
with miosis, muscle fasciculations, hypersalivation and rales
on auscultation. His wife stated that he drank malathion 2 h
earlier and explained that during the last month he had been
depressed and refused to eat. After intubation, gastric lavage
was done. Atropine 3 mg iv and infusions were administered.
At admission to the National Poison Control Center (NPCC),
5 h after deliberate ingestion of malathion, the patients was
in a coma, unresponsive to noxious stimuli. His vital signs
were as follows: blood pressure 120/80 mmHg, pulse
40/min, and respiratory rate 26/min. Physical examination
showed copious bronchial secretion and pinpoint pupils.
Soon after admission, myoclonic leg jerks and respiratory in-
sufficiency developed. During the first 30 min the patient re-
ceived 12 mg of atropine and activated charcoal was admin-
istered. The patient was transffered to Intensive Care Unit
(ICU) in NPCC where intermittent positive pressure ventila-
tion (IPPV) was started and atropine continued as intrave-
nous infusion. Pralidoxime methylsulphate (200 mg/h as a
continuous infusion) and supportive treatment were admin-
istered. Routine laboratory tests were within normal limits,
except for white blood cell count 18.9 × 10
9/L (reference
range, 4.00–10.80 × 10
9/L). Blood gases showed acidosis
(pH 7.212, pO2 123 mmHg, Sat O2 97.2%, pCO2 35.5
mmHg, ABE – 12.6 mmol/L, and lactate 1.1 mmol/L).
First measurement of acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE) showed activity of 1,806 U/L
and 1,586 U/L. A significant reduction of activity of AChE
1198 U/L and BChE to 277 U/L occurred after 6 hours. Or-
ganophosphate and metabolites were confirmed in serum and
urine by liquid chromatography-mass spectrometry, based on
solid-phase extraction procedure, a chromatographic separa-
tion using an ACQUITY UPLC
® HSST3 column and mass
spectrometric detection in the positive ion mode. A mobile
phase consisted of Solvent A (5 mM ammonium formate pH
3.0) and Solvent B (0.1% acetic formate in methanol), in a
linear gradient (constant flow-rate 0.3 mL/min). Malathion
was confirmed in blood in concentration of 1.21 mg/L on the
day 1, and 0.22 mg/L on the day 2. In urine it was confirmed
in concentration of 0.54 mg/L the day 1, and 0.34 mg/L the
day 2, and malaoxon was detected in concentration of 0.12
mg/L and 0.13 mg/L respectively. After the first 27 h the pa-
tient was recovering and MV was no longer needed.
Two cholinesterase assays, monitored daily, showed
that AChE did not correlate well with the severity of poi-
soning, whereas BChE was more sensitive index of OP poi-
soning (AChE 1806–1198–1273 U/L–1384 U/L–1295 U/L–
1447 and BChE 1586–277–391 U/L–476 U/L–585 U/L–670
U/L).
After a well-resolved cholinergic crisis during the first
27 h, the generalized flaccid weakness of upper extremities
and neck muscles, worsening of ophtalmoplegia, with pro-
gressive respiratory insufficiency was registered on the day
3, which was explained as intermediate syndrome. The re-
petitive nerve stimulation test (hypothenar – n. ulnaris sys-
tem at 3 Hz), at admission showed insignificant compound
muscle action amplitude (CMAP) decrement, that progressed
to 30% of CMAP amplitude decrement on the day 5, related
to post-synaptic failure of neuromuscular transmission.
Pralidoxime methylsulphate therapy was administered until
the day 8 with the total dose of 38.4 g, and atropine until the
day 10 (total dose 922 mg). The mechanical ventilation was
continued from the day 3 until the day 10. After that the of
the patient condition improved steadily and on the day 21 he
was disharged from the hospital.
Discussion
The pathophysiology of IMS, despite a high incidence
(10%–68%), remains unclear
 1. Some clinicians suggest that
IMS may result from inadequate oxime therapy (subdosage,
shorter duration of therapy, modality of administration), al-
beit there are others who feel that oximes are not necessary
or even deny the existence of IMS explaining delayed dete-
rioration among OP-poisoned patients by hypo-
atropinisation
 3–5.
The case presented in this paper refer to the patients
with severe malathion poisonings, admitted to hospital more
than 5 h after ingestion, implying possible risk for poor re-
sponse to the therapy. Gastric lavage was made in the local
hospital, 2 h after the ingestion. The American Academy of
Clinical Toxicology and the European Association of Poison
Centers and Clinical Toxicologists position paper suggests
that “gastric lavage should not be performed routinely, but it
should be considered only if a patient has ingested a poten-
tially life-threatening amount of a poison, and the procedure
can be undertaken within 60 minutes of ingestion”
 6. Admini-
stration of activated charcoal in conventional doses, is gener-
ally recommended for reducing further absorption of OP
pesticides, and all of our patients received it in single doses.
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and some new data from a randomized controlled trial
(RCT), aimed to assess efficacy of routine treatment with
multiple-dose activated charcoal, showed no benefit com-
pared to a treatment with the single use of charcoal
 7.
Pralidoxime methylsulphate was applied as a continu-
ous infusion (200 mg/h), but it could not prevent the devel-
opment of IMS. The explanation for that might be a delayed
treatment and insufficient pralidoxime dose (200 mg/h) but
also the chemical structure and lipophilicity of ingested OP.
The clinical usefulness of oximes has been challenged for
decades by toxicologists throughout the world
 8–9. The pau-
city of data from RCT, disparate results with oxime treat-
ment ranging from benefit to harm, could be explained by
substantial delay to the treatment, type and dose of OP, and
different therapeutic protocols that included pralidoxime in
doses from 1g every 6 h to 1g per h. Only one RCT so far
compared the World Health Organization (WHO) recom-
mended doses (30 mg/kg/h followed by 8 mg/kg/h continu-
ously) with placebo. This trial showed no clinical benefits
and a trend towards harm, despite a clear evidence that
reactivation of acetylcholinesterase was achieved 
9.
There are other proposed mechanisms of IMS which in-
clude different susceptibility of various cholinergic recep-
tors, muscle necrosis, downregulation or desensitization of
postsynaptic acetylcholine receptors, failure of postsynaptic
acetylcholine release, and oxidative stress-related myo-
pathy 
10–14. In our patient, who had nicotinic sings of OP poi-
soning, the level of creatine phosphokinase was normal as
well as the level of aspartate aminotransferase normal, so this
could not have been the cause of IMS.
The presented patient developed the clinical picture of
IMS within the first 72 h after the ingestion of OP formula-
tion in a suicide attempt. Though other signs of IMS poi-
soning were present, it was the respiratory insufficiency that
drew medical attention to the onset of the syndrome.  At that
time, no significant decrease of AChE and BChE compared
to the initial values was registered.
Repetitive stimulation test in the patient with malathion
poisoning showed post-synaptic failure of neuromuscular
transmission, implying the development of IMS, in accor-
dance with the study of Jayawardane et al 
15. In a prospective
study of 70 patients with OP poisoning, the authors identified
a series of stereotipic electrophysiological changes associ-
ated with IMS.
The risk of death in IMS is as high as it is in the choli-
nergic crisis. A prolonged clinical medical supervision after
recovery from the cholinergic crisis is necessary because of
the risk of IMS appearance. Based on this presentation, that
the cornerstone of IMS management is supportive therapy,
essentially directed towards the treatment of rapidly devel-
oping respiratory distress and respiratory failure. Any delay
in instituting mechanical ventilation will result in death
 1–3, 15.
However, whilst it is not expected that atropine therapy
would merit in the IMS, as the symptoms and signs are
clearly not muscarinic, oxime given during the cholinergic
crisis might be effective if it reactivates AChE. However, the
optimal oxime dose is yet to be determined 
16–17.
Conclusion
IMS is a major contributing factor of morbidity and
mortality related to organophosphate poisoning. In our patient,
continuous pralidoxime methylsulphate infusion did not pre-
vent the development of IMS, most likely due to the delayed
treatment and insufficient oxime dose, but also the chemical
structure and lipophilicity of ingested OP. Although the effi-
ciency of atropine and oxime in IMS is limited, the admini-
stration of these drugs, after early aggressive gastrointestinal
decontamination, is recommended to be continued for a longer
period. However, prolonged clinical medical supervision and
respiratory care are specifically emphasized as the key of
management for the intermediate syndrome.
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